Lilly links up European ADC network, snagging Elahere rival in latest biotech buy

Eli Lilly is hoovering up European antibody-drug conjugate (ADC) startups. Months after making a move for Emergence Therapeutics, Lilly has struck a deal to buy one of its partners, Mablink Bioscience, to add more ADC technology and drug candidates to its portfolio.